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Lipoprotein lipase (LPL) is functionally active only as a dimer.
It is also generally assumed that the highly homologous hepatic
lipase functions as a dimer, but no clear evidence has been
presented. A hepatic lipase-like activity, also indicated as L-type
lipase, is present in adrenal and ovary tissues. This enzyme is
thought to originate from the liver and to be identical to hepatic
lipase. We determined the functional molecular mass of hepatic
lipase in rat liver, adrenal gland and ovary by radiation in-
activation, a method for determining the functional size of a
protein without the need of prior purification. Samples were
exposed to ionizing radiation at ®135 °C. Hepatic lipase activity
in liver homogenate showed a single exponential decay. The
functional molecular mass was calculated to be 63³10 kDa.
INTRODUCTION
Two extracellular lipases, lipoprotein lipase (LPL) and hepatic
lipase (HL), serve important roles in lipoprotein metabolism
[1–4]. Both enzymes are highly homologous.
LPL is found in extrahepatic tissues, i.e. heart, skeletal muscle
and adipose tissue. Its main function is the hydrolysis of
triacylglycerols in very-low-density lipoprotein and chylomicrons
[5,6]. HL is present in the liver and is believed to play a role in
the metabolism of high-density lipoprotein, intermediate-density
lipoprotein and chylomicron remnants [7–11]. In addition to the
liver, an immunologically related enzyme, sharing characteristics
with HL, has been found in adrenal gland and ovary [12,13]. This
enzyme is also indicated as L-type lipase.
After synthesis in the parenchymal cells LPL and HL are
secreted and extracellularly bound to specific binding sites
[14–19]. For adrenal gland and ovary the situation seems to be
more complex. In these tissues the HL gene is transcribed into a
truncated mRNA [20]. Function or catalytic properties of these
HL gene products are not known. The full-length message of HL
is missing in adrenal gland and ovary. It has been hypothesized
that these tissues acquire catalytically active HL from the liver.
In this model it is assumed that the enzyme, after being secreted
by the liver, is transported to the adrenal gland and ovary, where
it binds to specific binding sites [21,22]. Therefore the HL in
adrenal gland and ovary is supposed to be identical to the liver
enzyme.
It has been shown in studies of sedimentation equilibration,
gel filtration and radiation inactivation studies that the hom-
ologous enzyme LPL is only catalytically active as a dimer
[23–25]. The functional unit of HL has not been established yet.
Abbreviations used: LPL, lipoprotein lipase ; HL, hepatic lipase.
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Hepatic lipase activity in adrenal homogenate was found to have
a functional molecular mass of 117³16 kDa. The functional
molecular masses of the lipases partially purified from rat liver
perfusate, adrenal homogenate or ovarian homogenate showed
the same pattern, a target mass for the liver enzyme of 56³6 kDa
and a target mass of 117³14 kDa for the enzyme from adrenal
gland or ovary. In Western blot analysis the mass of the structural
units of hepatic lipase in liver was 57 kDa and in adrenal and
ovary tissue 51 kDa. We conclude that the functional unit of
hepatic lipase in the liver is a monomer. The enzyme in adrenal
gland and ovary is different from the liver and the functional unit
may be a dimer.
Because of its close homology with LPL it is generally assumed
that HL is also a dimer. Gel-filtration experiments yield con-
flicting results. Depending on the salt concentration molecular
masses of the native enzyme of 65–200 kDa have been found
[26–29]. HL easily aggregates when free in solution. Therefore
we employed radiation inactivation to estimate the functional
molecular mass of HL in liver, adrenal gland and ovary.
MATERIALS AND METHODS
Animals
Normally fed male Wistar rats, 200–250 g, were used for most
experiments. Female Wistar rats were used for the experiments
with ovaries. They were housed under controlled conditions :
temperature 20–22 °C, light on 07:00–19:00 h. They had free
access to Purina rat chow and water.
Tissue preparations
Rats were killed by decapitation and 20% (w}v) liver homo-
genate and 10% (w}v) adrenal homogenate were prepared in
PBS containing 10% (v}v) glycerol, pH 7.4 (15 s, Polytron,
setting 4). Aliquots (400 ll) of homogenate were sealed in 1 ml
glass ampoules, frozen in liquid nitrogen and stored at ®80 °C
until use.
Isolation of HL
HL was isolated from heparin-containing rat liver perfusate or
heparin-containing tissue extracts from rat adrenals and ovaries
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as described previously [13] with minor modifications. The
perfusate and tissue extracts were applied to a Sepharose–heparin
column. After washing the column with 3–6 column volumes of
10 mM sodium phosphate buffer, pH 7.4, containing 0.2 M NaCl
and 10% (v}v) glycerol, HL activity was eluted with the same
buffer containing 1 M NaCl and 1% BSA in addition. The peak
fractions were combined and the buffer was changed to PBS
containing 1% BSA and 10% glycerol by gel filtration using
PD10 columns. Aliquots (400 ll) of partially purified HL from
liver perfusate or tissue extracts of adrenals or ovaries were
sealed in 1 ml glass ampoules and frozen in liquid nitrogen.
Samples were stored at ®80 °C until use. SDS}gel electrophoresis
and Western blotting of the samples were performed as described
previously [30]. To quantify the amount of protein, gels or blots
were scanned with the Hewlett Packard Scan Jet IICX and
analysed.
Radiation inactivation and dosimetry
Samples were irradiated in a cryostat at ®135 °C, employing a
3 MeV Van de Graaff electron accelerator. The duration of the
electron pulse was 250 ns and the pulse had a 2 A peak current
as described previously [31]. To improve dose homogeneity a 0.3-
mm-thick aluminium scatter plate was used on top of the beam
window of the cryostat. Dosimetry was performed before each
irradiation experiment using FWT-60 radiochromic nylon film
dosimeters (1 cm¬1 cm), between 3-mm-thick nylon plates. The
dose received was determined from the change in absorbance at
510 nm and calculated from the formula:
Dose (kGy)¯ 151.6¬(DA)".")'
obtained by dose calibration of the FWT-60 films using a '!Co
source.
This resulted in a dose of 0.082 Gy}nC with an accuracy of
³5%. Electron pulses were given at a rate of 5 Hz. The charge
per pulse was determined before and after each irradiation and
was found to be stable within 1%. The relationship between the
molecular mass (M) and the dose is given by the equation M¯
c[K[St where c¯ 6400 kGy}kDa, St¯ 2.8 (correction factor
for the irradiation temperature of ®135 °C) and K¯ slope of the
ln (fractional activity A}Ao) versus dose plot [32]. A least-square
fit was calculated for the ln (remaining activity versus radiation
dose). The validity of our method was verified by determination
of the target mass of yeast glucose-6-phosphate dehydrogenase
[33]. We observed a monoexponential inactivation for this protein
corresponding to a target mass of 99³6 kDa, which is in line
with the molecular mass of the enzyme of 104 kDa.
Radiation inactivation of HL protein was followed by SDS}
PAGE according to the method of Laemmli on a 3% stacking
gel and a 10% resolving gel and subsequent Western blotting on
nitrocellulose paper. HL was identified on the blot using poly-
clonal goat anti-HL IgG and an alkaline phosphatase-conjugated
anti-(goat IgG) [30].
HL assays
HL triacylglycerol hydrolase activity was measured using an
artificial glycerol-[9,10(n-$H)]trioleate emulsion in gum arabic,
pH 8.5 [12]. To avoid any possible contamination with other
neutral lipase activities in the adrenal and liver homogenates, HL
activity was measured in samples preincubated with or without
an anti-HL-specific polyclonal antibody [34].
Materials
All chemicals used were of analytical grade. Heparin was
purchased from Leo Pharmaceutical Products, Weesp, The
Netherlands and BSA from Sigma (St. Louis, MO, U.S.A.).
Glycerol [9,10(n-$H)]trioleate was obtained from Amersham
International, Amersham, Bucks., U.K. Alkaline phosphatase-
conjugated anti-(goat IgG) was purchased from Tago,
Burlingame, CA, U.S.A.
RESULTS
HL in rat liver
HL activity in homogenate from rat liver, prepared in PBS
containing 10% (v}v) glycerol and 1% BSA, is stable and can be
frozen and thawed without loss of activity.
If frozen rat liver homogenate fractions were exposed to
increasing doses of radiation triacylglycerol hydrolase activity
showed a simple exponential decay. The functional molecular
mass was calculated to be 63³10 kDa (Figure 1). A similar
decay curve was observed on exposure of HL partially purified
from rat liver heparin perfusate. The calculated target mass was
56³6 kDa.
The target mass was also evaluated by SDS}gel electrophoresis
and immunoblotting. On Western blots HL had an apparent
molecular mass of 57 kDa. Upon radiation, immunoreactivity at
this position in the gel was lost. In parallel immunoreactive
material increased at the front of the gel, suggesting that
irradiation resulted in fragmentation of the protein (Figure 2).
The loss in HL-immunoreactive material at 57 kDa on the
Western blot upon irradiation yielded a target mass of 53³5 kDa
(Figure 3). We also followed the decrease in the amount of
albumin during irradiation at 66 kDa on the gel. For albumin a
target mass of 70³6 kDa was found.
Figure 1 Radiation inactivation of HL in liver
HL triacylglycerol hydrolase activity was measured in irradiated liver homogenate (E, broken
line) or in irradiated hepatic lipase (HL) purified from liver heparin perfusate (D, solid line)
as described in the Materials and methods section. Data are expressed as ln [activity measured
in the samples after irradiation (A) divided by the HL activity of non-irradiated samples (Ao)].
The fitted line is from least-square analysis. Values plotted are the means of three
determinations from five separate experiments.
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Figure 2 Western blot of irradiated partly purified HL
Partly purified HL was irradiated as described in the Materials and methods section. After
radiation the samples were mixed with SDS/PAGE sample buffer, electrophoresed on
SDS/PAGE and subjected to Western blot analysis.
Figure 3 Irradiation fragmentation of HL protein
The fraction of surviving immunoreactive protein of hepatic lipase (HL, E) or BSA (D)
[ln (A/Ao)] is plotted as a function of radiation dose. HL-immunoreactive protein was measured
at 57 kDa on Western blots. The amount of BSA was measured as the amount of protein at
66 kDa on SDS-gels. To quantify the amount of protein, gels or blots were scanned with the
Hewlett Packard Scan Jet IICX and analysed.
HL in rat adrenal gland and ovary
Tissue homogenate of rat adrenals was exposed to increasing
doses of radiation. A target mass of 117³16 kDa was found,
which is much larger than in liver (Figure 4A). Because the HL
activity in ovary was not sufficient to employ radiation in-
activation in the homogenate, we purified the enzyme from
ovaries and adrenals. The same target mass as for the lipase
activity in the adrenal homogenate was obtained for the purified
HL from rat adrenal gland and ovary, i.e. 117³14 kDa (Figure
4B).
Structural unit of HL
Besides the size of the functional unit, we also compared the size
of the structural unit of the liver enzyme and the enzyme in
adrenal gland and ovary with SDS}gel electrophoresis and
Figure 4 Radiation inactivation of HL in liver, adrenal gland and ovary
HL triacylglycerol hydrolase activity was measured in (A) irradiated liver homogenate (E) or
adrenal homogenate (D) ; or (B) irradiated HL partly purified from liver heparin perfusate (E),
or heparin-containing homogenates of adrenals (D) or ovaries (_) as described in the
Materials and methods section. Data are expressed as ln [activity measured in the samples after
irradiation (A) divided by the activity in non-irradiated samples (Ao)]. The fitted line is from least-
square analysis. The values plotted are the means from 3–5 different experiments.
immunoblotting. In liver a structural unit of 57 kDa was found
compared with a structural unit of 51 kDa in adrenal gland and
ovary (Figure 5).
DISCUSSION
Employing radiation inactivation, we show that the functional
target mass of HL in rat liver is 63 kDa, in the adrenal gland and
in the ovary it is 117 kDa. The structural unit in liver is 57 kDa
and in the adrenal and ovary 51 kDa, as measured by Western
blotting. Using radiation target mass analysis the molecular mass
of the enzyme can be determined in its native state, bound to its
binding site, without prior purification. In this way purification
artefacts are avoided. Moreover, radiation inactivation reveals
functional interactions among enzyme complexes with receptors
or in oligomeric enzyme systems. After purification the sizes of
the functional units of the liver and the adrenal or ovarian
enzyme were respectively 56 and 117 kDa, similar to the values
observed in crude homogenate. Therefore it seems that in-
teraction of the enzyme with its binding site does not influence
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Figure 5 Determination of the size of the structural unit of HL in adrenal
gland and ovary
Partly purified HL from heparin-containing liver perfusate (lane 1) or from heparin-containing
homogenate of adrenals (lane 2) or ovaries (lane 3) were subjected to SDS/PAGE and Western
blotting to determine the size of the structural unit.
the activity of the enzyme. The reported molecular mass of HL
in liver, as estimated by SDS}gel electrophoresis, is in the range
55–66 kDa [28,29,35,36]. The value obtained with gel filtration
varies between 65 and 200 kDa [26–29]. The variation in the
observed values of the enzyme in its native state may be due to
association of the enzyme with specific or non-specific HL-
binding proteins or to aggregation of the enzyme. The monomeric
value of the molecular mass of HL after gel filtration as observed
by Ikeda et al. [29] gives no information about the size of the
functional unit ; formation of dimeric HL in the lipase assay
cannot be excluded, because for LPL also, which is clearly a
dimer, Ikeda observed a monomeric value of the molecular mass
after gel filtration. The target size of both the native liver enzyme
in the homogenate and the purified liver enzyme as measured by
radiation inactivation indicates that the functional unit of HL in
liver is a monomer. This is in contrast to LPL. Using a number
of techniques including radiation inactivation the functional unit
of LPL has been shown to be a dimer [23–25]. The dimeric
functional unit of LPL refers to its triacylglycerol hydrolase
activity, for its esterase activity there is no need for a dimeric
structure [37]. For LPL it is assumed that the dimeric structure
is a prerequisite for the binding of the water-insoluble triacyl-
glycerol. The proposed model for the LPL structure is a model
consisting of two monomeric LPL units arranged in such a
manner that the C-terminal domain, the lipid-binding domain of
one subunit, is close to the N-terminal domain, the catalytic
domain of the other subunit, in a so called head-to-tail ar-
rangement [38,39]. Based on the close relationship between HL
and LPL it is assumed that the functional unit of HL is also
dimeric. However, it appears that HL in liver is a monomer
rather than a dimer. Therefore, it may well be that the interaction
of HL, or at least the liver enzyme, with its substrate triacyl-
glycerol is different from the proposed interaction of LPL with
its substrate.
For the size of the functional unit of the enzyme from adrenal
gland or ovary a much higher target mass was found than for the
liver enzyme, i.e. 117 kDa. Despite this higher target size, we
found a smaller size of structural unit of the HL from adrenal
gland and ovary, 51 kDa. This is lower than for the liver enzyme,
but similar to the size that was reported for the adrenal gland by
Doolittle et al. [21]. Since we found a functional unit of 117 kDa
for the adrenal and ovarian enzyme, both in the crude homo-
genate and after purification, we conclude that the enzyme in
adrenal gland and ovary is in a dimeric form. The difference
between the liver enzyme and the enzyme in the adrenal gland or
ovary is unexpected as it was assumed that the enzyme in these
tissues is derived from the liver [21,22]. This suggests that HL is
present in the liver as a monomer and is dimerized after or during
its transport to the adrenals and ovaries. Radiation inactivation
of the liver enzyme would lead to inactivation of only one
monomeric subunit, radiation inactivation of the adrenal or
ovarian enzyme on the other hand, would lead to inactivation of
both subunits because of energy transfer between the two
monomeric subunits. The size of the structural unit in the
adrenal gland and ovary is also different from that in the liver,
indicating that post-translational modification of the enzyme
occurs in the liver or during its transport from the liver to the
adrenal. Liver and adrenal enzymes differs also in binding
characteristics. The release of HL from the liver and from the
adrenal gland by protamine is different [40]. No significant
release of HL was found in the adrenal gland after injection of
protamine, while protamine was as effective as heparin in the
release of HL from liver. It was concluded that this may be due
to a difference in the binding site for HL in liver and adrenal
gland. However, the observed difference in the release of HL
could also indicate that the adrenal enzyme is more tightly bound
because of its dimeric functional unit. The release of the
homologous dimeric enzyme LPL by protamine injection was
also very low and only 10% of the amount of LPL released by
heparin.
In this paper we have shown that HL in liver is in the
monomeric form and different from HL in the adrenal gland and
ovary, which is in the dimeric form. Whether the size of the
functional and structural unit as well as the substrate specificities
or physiological function of HL in the adrenal gland and ovary
are different is currently under investigation.
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